IQVIA Holdings Inc (IQV)
Pretax margin
| Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | ||
|---|---|---|---|---|---|---|
| Earnings before tax but after interest (EBT) | US$ in thousands | 1,674,000 | 1,459,000 | 1,351,000 | 1,129,000 | 351,000 |
| Revenue | US$ in thousands | 15,403,000 | 14,308,000 | 14,004,000 | 13,470,000 | 10,935,000 |
| Pretax margin | 10.87% | 10.20% | 9.65% | 8.38% | 3.21% |
December 31, 2024 calculation
Pretax margin = EBT ÷ Revenue
= $1,674,000K ÷ $15,403,000K
= 10.87%
The pretax margin of IQVIA Holdings Inc has shown a positive trend over the past five years. Starting at 3.21% in December 2020, the pretax margin has progressively increased to 10.87% by December 2024. This indicates that the company has been effectively managing its expenses relative to its revenue, resulting in higher profitability before taxes. The consistent improvement in pretax margin reflects a strong financial performance and effective cost control measures implemented by IQVIA Holdings Inc.
Peer comparison
Dec 31, 2024
Company name
Symbol
Pretax margin
IQVIA Holdings Inc
IQV
10.87%
Arrowhead Pharmaceuticals Inc
ARWR
-17,351.20%
Charles River Laboratories
CRL
2.18%
Exelixis Inc
EXEL
31.43%
Incyte Corporation
INCY
7.47%
Medpace Holdings Inc
MEDP
22.57%